IBOGAINE Act Seeks to Strengthen Federal Fast-Track for Psychedelic Therapies in the U.S.

The new IBOGAINE Act aims to legally establish federal support for ibogaine and other psychedelic therapies, with a primary focus on veterans and mental health treatment. This legislation seeks to expedite the development and clinical approval of psychedelic-assisted therapies through the FDA's breakthrough therapy designation pathway. The initiative addresses the growing mental health crisis affecting military veterans, particularly those with treatment-resistant conditions. By codifying federal support into law, the act aims to accelerate research and access to these novel therapeutic approaches for individuals who have not responded to conventional psychiatric medications.